ESTRO 2020 Abstract book

S365 ESTRO 2020

(β:0.275;SE:0.025;p=0.018). A higher empathic concern was significantly associated to increased CS (β:2.227;SE:0.422;p<0.001), STS (β:1.651;SE:0.414;p<0.001), with no significant effect on BOS (β:0.059;SE:0.298;p=0.070). The final multivariable model included alexithymic traits on TAS-20 as the only indipendent predictive variable for BOS (p=0.018). Conclusion The PRO BONO study provided an overview of BOS, alexithymia and empathy among RTTs. Alexithymic personality trait increased the likelihood to develop BOS, with less professional satisfaction. This finding can be potentially used to screen professionals at risk to implement effective preventive measures. SP-0594 Survival in a competitive learning environment: how to communicate better P. Gulbrandsen 1 1 University of Oslo, Institute of Clinical Medicine, Campus Ahus- Mail Drawer 1000- Akershus University Hospital- 1478 Lørenskog, Norway Abstract text Health care is one of society’s most fascinating arenas: stakes are high, changes in technology and knowledge are rapid, activity is meaningful, challenging, gratifying, and inspiring. Despite resource constraints, the sector therefore attracts people with high intellectual capacities, ambitions, and working capacity. Historically, the field is hierarchical with clear boundaries between people with different tasks, usually also expressed by uniforms they carry. This means that most conversations in health care are asymmetric, that is, functions of people who talk together are complementary and a power difference is present. Asymmetric talks are different from everyday colloquial conversations in many ways. Yet most health care workers have not been taught how they are different, and how much this difference influences the process and outcome of talks at work. Hence, many feel a need to know more about how to communicate with superiors or assistants, have efficient team meetings, avoid conflict, deal with annoyed or disappointed colleagues, provide constructive feedback, handle criticisms, and set personal boundaries. This talk will provide some simple principles to come closer to achieving better interaction and collaboration with colleagues. Basic steps are the understanding of: a) How talk works in general b) How talk works in your current interaction with someone c) How you can talk to achieve what you hope to, based on b) Symposium: Communication in professional life / how to communicate within the team

Cardiology, Sydney, Australia ; 3 Ingham Institute of Applied Medical Research, Department of Biostatistics, Sydney, Australia ; 4 Macarthur Cancer Therapy Centre, Department of Medical Oncology, Sydney, Australia ; 5 Liverpool Hospital, Department of Radiation Oncology, Sydney, Australia ; 6 Ingham Institute of Applied Medical Research, Department of Medical Physics, Sydney, Australia ; 7 University of Wollongong, Centre of Medical Radiation Physics, Sydney, Australia ; 8 University of Sydney, Sydney Medical School, Sydney, Australia Purpose or Objective Cardiovascular (CV) sequelae after adjuvant therapy remains an important issue in breast cancer (BC) survivors. This study aimed to determine the impact of adjuvant therapy on CV sequelae in breast cancer patients. Material and Methods Patients diagnosed with Stage I-III breast cancer between 2006-2015 and treated with adjuvant therapy within South Western Sydney were retrospectively identified. Clinico- demographic and adjuvant treatment details including chemotherapy, Trastuzumab, endocrine therapy and radiotherapy were extracted from oncology records and matched with a cardiology database. Patients who developed a new or worsening pre-existing CV condition, coded as per ICD-10 classification, and categorised as at least moderate or severe on relevant investigations, were defined as ‘index’ cases. The time interval between breast cancer and CV condition were classified as ‘acute’ (0-6 months), ‘sub-acute’ (6-24 months) and ‘chronic’ (>24 months) respectively. Overall cohort and index group details were summarised descriptively. Fisher’s exact test was performed to compare and analyse the effect of cancer treatments on index versus non-index cases. Results Of 3608 patients, there were n=1522 Stage I, n=1526 Stage II and n=560 Stage III, aged 22-98 years (mean 59 years). A total of 1555 (43%) received chemotherapy, n=379 (11%) received Trastuzumab, n=2655 (74%) received radiotherapy (RT) and n=2605 (72%) endocrine therapy. There were n=176/3608 (5%) index cases comprising n=272 CV conditions, including n=30 (11%) pre-existing conditions which worsened post BC treatment. CV conditions included valvular heart disease (n=70/272), heart failure (n=62/272), ischaemic heart disease (n=61/272), arrhythmia (n=49/272), cardiomyopathy (n=10/272) and pericardial effusion (n=8/272). Of note, n=103/176 ‘index’ cases experienced multiple CV conditions. Of these, n=25/272 (9%) were classified as acute, n=79/272 (29%) as sub-acute and 148/272 (54%) as chronic. Half of the index cases had ≥2 CV risk factors with n=72/176 (41%) receiving chemotherapy, n=25/176 (14%) Trastuzumab and n=123/176 (70%) endocrine therapy. Of the n=134/176 (76%) who received radiotherapy, predominantly a 50Gy/25 or 42.4Gy/16 fraction course, n=88/134 (66%) received tangential RT and n=46/134 (34%) regional nodal irradiation. Mean heart dose (pre-DIBH era) for the n=46 evaluable left-sided RT cases ranged from 0.63-6.8Gy (mean=2.5Gy). Patients undergoing RT had an increased risk of heart failure (p=0.004) and valvular heart disease (p=0.04). No significant relationship was found between chemotherapy, Trastuzumab and/or endocrine therapy exposure and the subsequent risk of CV sequelae. Conclusion A range of cardiovascular conditions were observed after adjuvant therapy for breast cancer. Radiotherapy was associated with an increased risk of cardiovascular sequelae. Cardiovascular health remains an important

Poster Highlights: Poster highlights 19 CL : Breast

PH-0595 Cardiovascular sequelae after adjuvant therapy in a 10-year cohort of breast cancer patients. Z. LI 1 , A. Satchithanandha 1 , A. Hopkins 1,2 , J. Otton 1,2 , J. Descallar 1,3 , D. Adams 1,4 , S. Tang 1,5 , M. Field 1,6 , V. Batumalai 1,5 , L. Holloway 1,5,6,7,8 , G. Delaney 1,5 , E. Koh 1,5 1 University of New South Wales, South Western Sydney Clinical School, Liverpool, Australia ; 2 Liverpool Hospital,